Tag Archives: health

Criminal Activity of Cannabis Related Crimes and Youth Decreased by Half

Share

According to the Incident-Based Crime Statistics Database, cannabis crimes associated with youth decreased by half in the last five years in Ontario.

The majority age associated with cannabis production, trafficking and distribution is between 12 to 21 in Canada. By 2017, the rates of cannabis-related criminal activity committed by youth and adults was almost equal.

In Ontario, the crime rate for youth cannabis crimes dropped to 15.27 in 2017. In 2013, the rate was 37.45.

Despite this decrease, charges were laid on youth three times more than adults. However, these numbers do not include juveniles who were not charged.

In October, people who are nineteen and older will have legal access and possession of cannabis. It will still be illegal to sell cannabis to adolescence.

However, experts and substance and health specialists predict youth will be more open to discuss using cannabis to get the help they need.

Eugene Oscapella, a professor of criminology at the University of Ottawa, says drug policy is a human rights and justice issue.

“We are taking people, we’re stigmatizing them, we’re criminalizing them, we’re impairing their ability to earn a living, we’re impairing their ability to travel, we’re intruding their privacy and their private behavior, so there’s all sorts of human rights issues involved,” says Oscapella.

Oscapella says most pot sales are made by juveniles. The common age of first using cannabis is 16 or 17, and the heaviest consumption is between 15 to 24.

He adds there will be a reduction of some parts of crime one cannabis becomes legal, but there will still be a black-market targeting youth. However, he adds they will not likely be accessing cannabis through typical organized crime.

The Wellness Centre has access to a list of resources for counselling for substance abuse and mental health. Fa’Ttima Omran referred to the Amethyst Women’s Addiction Centre and the Distress Centre Ottawa for cannabis addiction. Photo by Katie Jacobs.

“It might be somebody’s older brother going into a store and buying cannabis … and selling it to younger kids and taking a small profit,” says Oscapella.

Oscapella says the most fundamental solution is to understand why people use drugs, why do some use it in a problematic way, and how do we help them.

Health specialists, such as Jessica Brett, a nurse at Ottawa Public Health (OPH) for three years, is working on putting together public education and policy analyses in preparation for legalization.

She says OPH supports legalization, specifically using regulations for the public’s best interest in health.

Brett says that criminalizing cannabis leads people, particularly youth, to experience social harms.

“Legalizing … hopefully will be able to address negative effects associated with cannabis use and hopefully minimize those social harms that we currently see,” says Brett.

Brett adds OPH will be encouraging youth under the age of 25 not to use it since it can change functions of the brain during adolescence, and can lead to mental health problems.

Fa’Ttima Omran, a second-year master’s student in legal studies, says with legalization, there may be more opportunities to have interesting discussions on cannabis addiction.

“There is a climate of change that … is making sure that individuals that are very vulnerable will not get caught up in the criminal justice system just because of their usage,” says Omran.

Omran is the administrative coordinator of the Wellness Centre at Carleton University. She says it’s more important to understand the social, political and mental health aspects behind cannabis use rather than criminalizing the person.

“People do seek counselling for using alcohol, for using all different substances, and it just brings into the conversation what addiction has within our society …and making sure that people that are experiencing that feel they are supported in any way possible in the most non-judgmental ways,” says Omran.

Omran says the Wellness Centre is designed to be a safe, non-judgmental space where information is confidential. The centre also has access to counselling resources outside the University.

Cannabis in Crimes Canada- Working Copy

B.C. government looks to save millions in prescription drug costs

Share
COSSETTE-Etanercept_Enbrel
A patient holds an Enbrel auto-injector syringe. Enbrel (Etanercept) is one of several biologic drugs used to treat rheumatoid arthritis. (Creative Commons licence provided courtesy of Flickr user mnicolem)

Faced with soaring prescription costs, the B.C. government is looking for alternatives to expensive biologic drugs, not long ago hailed as revolutionary.

Used to treat debilitating joint disorders like rheumatoid arthritis, biologics were “game-changers” when they were first invented 15 to 20 years ago, said Dr. Jason Kur, president of the B.C. Society of Rheumatologists.

Biologics are genetically-engineered proteins, developed using living cells. As such, they are far more complex — and costly — than drugs manufactured through a conventional chemical process.

According to documents obtained through an access to information request, B.C. PharmaCare spent a record $82.5 million in 2014 to treat the three most common forms of inflammatory arthritis using biologics. That’s more than 12 times the amount the province spent on these medications when they were first introduced in 2002.

Excerpt from an information note provided to B.C. Health Minister Terry Lake
Click annotation to see full document



With an annual cost of around $20,000 per patient, one drug alone — Infliximab — accounted for $51 million in spending in 2012-13: PharmaCare’s single largest drug expenditure that fiscal year.

Documents also show the number of patients receiving PharmaCare coverage for a biologic to treat one of the three most common forms of inflammatory arthritis grew more than tenfold, from 547 patients in 2002 to over 6,400 patients in 2014.

Cheryl Koehn understands the importance of biologics first-hand.

A former Olympic-calibre volleyball player, she was just 27 when she developed rheumatoid arthritis 27 years ago.

“Before these drugs, we basically were left at home to become disabled and die,” said Koehn, who now works as founding president of Arthritis Consumer Experts, a national organization offering science-based information to Canadians living with arthritis.

But PharmaCare administrators hope subsequent entry biologics (SEBs) will offer not only comparable patient results, but also huge savings to the province.

Biologics cannot be perfectly replicated, but SEBs — or “biosimilars” — have been shown to offer similar relief of patients’ symptoms. In other words, they are designed to be comparable, but not identical to the original biologic on which they are based. Importantly, they are also developed to be significantly less expensive.

Since Feb. 19, 2016, a biosimilar of Infliximab — Inflectra — has been available through PharmaCare, priced about a third lower than the original Infliximab. Inflectra is also listed in provincial drug coverage plans in Ontario and Quebec, and will be available in Manitoba in April.

Excerpt from B.C. PharmaCare’s February 2016 newsletter
Click annotation to see full document


Kur said he and his colleagues are “cautiously optimistic” about the arrival of biosimilars in B.C.

“We’re all quite aware these are some of the biggest costs driving drug expenditures,” he said, adding there are some lingering concerns.

Many of the original biologics have more than one or two decades’ worth of data to support their safety and efficacy, he said. “That’s not something that should be taken lightly.”

Still, Kur supports the B.C. government’s decision to have Inflectra prescribed to patients who have never before taken Infliximab. Long-term studies conducted in Europe strongly suggest the drug is just as safe and effective as the original biologic.

Koehn, too, agrees that SEBs offer an exciting opportunity, especially if the provincial government re-invests savings to expand coverage to other biologics and SEBs.

She also hopes the government might relax some of the eligibility criteria, which require patients to take less effective medication before being considered for a biologic.

Only biologics and SEBs, said Koehn, can restore up to 50, 70 or even 90 per cent of a patient’s health.

“It’s like saying to a cancer patient, ‘We’ll get rid of 20 per cent of your tumour and tough luck with the rest,’” said Koehn. “You don’t say that to cancer patients, so why should you say that to people with auto-immune arthritis?”

Additional information and ATI requests

B.C. Ministry of Health – Information note and additional information

ATI request – Federal government – Public Safety Canada

ATI request – Provincial government – Ontario Ministry of Community Safety and Correctional Services

ATI request – Municipal government – City of Ottawa

ATI request – Federal government (previously completed request) – Foreign Affairs, Trade and Development Canada